8-K
DAXOR CORP (DXR)
UNITEDSTATES
SECURITIESAND EXCHANGE COMMISSION
Washington,D.C. 20549
FORM8-K
CURRENTREPORT
Pursuantto Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) February 2, 2022
DaxorCorporation
(Exact name of registrant as specified in its charter)
| New<br> York | 811-22684 | 13-2682108 |
|---|---|---|
| (State<br> or other jurisdiction | (Commission | (IRS<br> Employer |
| of<br> incorporation) | File<br> Number) | Identification<br> No.) |
| 109<br> Meco Lane, Oak Ridge, TN | 37830 | |
| --- | --- | |
| (Address<br> of principal executive offices) | (Zip<br> Code) |
212-330-8500
Registrant’s telephone number, including area code
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title<br> of each class | Trading<br> Symbol(s) | Name<br> of each exchange on which registered |
|---|---|---|
| Common<br> Stock $0.01 par value | DXR | NYSE<br> AMERICAN |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Item8.01 – Other Events
On February 2, 2022 Daxor Corporation (Nasdaq:DXR) (the “Company”) issued a press release announcing the Company commenced trading on the Nasdaq Capital Markets as of February 2, 2022 and will visit the Nasdaq Market Site on Friday, February 4, 2022 to ring the Opening Bell. The press release issued is attached to this filing as Exhibit 99.1
Item9.01 Exhibits
(d) Exhibits. The following exhibit is filed with this Current Report on Form 8-K:
| No. | Description |
|---|---|
| 99.1 | Press release dated February 2, 2022 – Daxor Corporation Commences Trading on The NASDAQ Capital Market |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| DAXOR CORPORATION | ||
|---|---|---|
| (Registrant) | ||
| Date:<br> February 2, 2022 | By: | /s/ Robert J. Michel |
| Name: | Robert<br> J. Michel | |
| Title: | Chief<br> Financial Officer |
Exhibit99.1
DaxorCorporation Commences Trading on The NASDAQ Capital Market
Management to Ring the Nasdaq Stock Market Opening Bell on February 4, 2022
OakRidge, TN – February 2, 2022 – Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces it commenced trading on the NASDAQ Capital Markets as of today, February 2, 2022 and will visit the Nasdaq MarketSite in Times Square on Friday, February 4, 2022. In honor of the occasion, Michael Feldschuh, CEO & President will ring the Opening Bell.
“We are thrilled to commence trading on the NASDAQ Capital Markets today and believe that this milestone enables Daxor to better position the company to capitalize on Nasdaq’s long tradition of listing category-defining medical technology companies. This aligns well with Daxor’s innovative blood volume technology portfolio,” commented Michael Feldschuh, CEO and President of Daxor. “This move will improve the visibility of our stock, enhance trading liquidity in our shares, and provide us with greater exposure to institutional investors.”
Where:
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
When:
Friday, February 4, 2022 – 9:15 a.m. to 9:30 a.m. ET
Daxor Media Contact:
Linda Dyson
516-222-2560
Linda@coreir.com
Nasdaq MarketSite Media Contact:
Peter Gau
(201) 388-9682
Peter.gau@nasdaq.com
Feed Information:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK
Social Media:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:
http://www.facebook.com/nasdaq.
For photos from ceremonies and events, please visit our Instagram page:
http://instagram.com/nasdaq
For news tweets, please visit our Twitter page:
http://twitter.com/nasdaq
Webcast:
A live stream of the Nasdaq Opening Bell will be available at:
https://www.nasdaq.com/marketsite/bell-ringing-ceremony
Photos:
To obtain a hi-resolution photograph of the Market Open, please go to https://www.nasdaq.com/marketsite/bell-ringing-ceremony and click on the market open of your choice.
AboutDaxor Corporation
Daxor Corporation (Nasdaq: DXR) is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 60,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing multicenter trials in the areas of COVID-19 and heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor’s mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com.
Forward-LookingStatements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
InvestorRelations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
516-222-2560
brets@coreir.com